Cancer vaccines: Between the idea and the reality

被引:493
作者
Finn, OJ [1 ]
机构
[1] Univ Pittsburgh, Sch Med, Inst Canc, Dept Immunol, Pittsburgh, PA 15261 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1038/nri1150
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Whether vaccines are designed to prepare the immune system for the encounter with a pathogen or with cancer, certain common challenges need to be faced, such as what antigen and what adjuvant to use, what type of immune response to generate and how to make it long lasting. Cancer, additionally, presents several unique hurdles. Cancer vaccines must overcome immune suppression exerted by the tumour, by previous therapy or by the effects of advanced age of the patient. If used for cancer prevention, vaccines must elicit effective long-term memory without the potential of causing autoimmunity. This article addresses the common and the unique challenges to cancer vaccines and the progress that has been made in meeting them. Considering how refractory cancer has been to standard therapy, efforts to achieve immune control of this disease are well justified.
引用
收藏
页码:630 / 641
页数:12
相关论文
共 173 条
  • [131] Ranieri Elena, 2000, Immunological Investigations, V29, P121, DOI 10.3109/08820130009062294
  • [132] Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations
    Rebbeck, TR
    Lynch, HT
    Neuhausen, SL
    Narod, SA
    van't Veer, L
    Garber, JE
    Evans, G
    Isaacs, C
    Daly, MB
    Matloff, E
    Olopade, OI
    Weber, BL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (21) : 1616 - 1622
  • [133] RANDOMIZED TRIAL OF MONOCLONAL-ANTIBODY FOR ADJUVANT THERAPY OF RESECTED DUKES-C COLORECTAL-CARCINOMA
    RIETHMULLER, G
    SCHNEIDERGADICKE, E
    SCHLIMOK, G
    SCHMIEGEL, W
    RAAB, R
    HOFFKEN, K
    GRUBER, R
    PICHLMAIER, H
    HIRCHE, H
    PICHLMAYR, R
    BUGGISCH, P
    WITTE, J
    EIGLER, FW
    FACKLERSCHWALBE, I
    FUNKE, I
    SCHMIDT, CG
    SCHREIBER, H
    SCHWEIBERER, L
    EIBLEIBESFELDT, B
    [J]. LANCET, 1994, 343 (8907) : 1177 - 1183
  • [134] Salgaller ML, 1998, J SURG ONCOL, V68, P122
  • [135] Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma
    Salgia, R
    Lynch, T
    Skarin, A
    Lucca, J
    Lynch, C
    Jung, K
    Hodi, FS
    Jaklitsck, M
    Mentzer, S
    Swanson, S
    Lukanich, J
    Buena, R
    Wain, J
    Mathisen, D
    Wright, C
    Fidias, P
    Donahue, D
    Clift, S
    Hardy, S
    Neuberg, D
    Mulligan, R
    Webb, I
    Sugarbaker, D
    Mihm, M
    Dranoff, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) : 624 - 630
  • [136] Sallusto F, 2000, CURR TOP MICROBIOL, V251, P167
  • [137] Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
    Scanlan, MJ
    Gure, AO
    Jungbluth, AA
    Old, LJ
    Chen, YT
    [J]. IMMUNOLOGICAL REVIEWS, 2002, 188 : 22 - 32
  • [138] Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer
    Schlom, J
    Kantor, J
    Abrams, S
    Tsang, KY
    Panicali, D
    Hamilton, JM
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1996, 38 (01) : 27 - 39
  • [139] Schmielau J, 2001, CANCER RES, V61, P4756
  • [140] Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells
    Schuler-Thurner, B
    Schultz, ES
    Berger, TG
    Weinlich, G
    Ebner, S
    Woerl, P
    Bender, A
    Feuerstein, B
    Fritsch, PO
    Romani, N
    Schuler, G
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (10) : 1279 - 1288